

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Non-Hodgkin Lymphoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. In the Phase III STARGLO trial, the combination of glofitamab and gemcitabine/oxaliplatin resulted in which of the following outcomes in comparison to rituximab with gemcitabine/oxaliplatin for patients with transplant-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)?**

 - Inferior overall survival (OS)
 - Noninferior OS
 - Significantly improved OS
- 2. A subgroup analysis of progression-free survival (PFS) and OS from the Phase III POLARIX trial suggests that the regimen of polatuzumab vedotin-R-CHP may be more efficacious in which patients with newly diagnosed DLBCL?**

 - Patients with germinal center B cell-like cell-of-origin subtype
 - Patients with activated B-cell-like cell-of-origin subtype
 - Patients with bulky disease present
 - Patients younger than age 65
- 3. Which of the following best describes outcomes from the Phase III inMIND trial comparing the triplet combination of tafasitamab with lenalidomide/rituximab (R2) to R2 alone in patients with relapsed/refractory follicular lymphoma?**

 - PFS was similar in both study arms
 - PFS was significantly improved with R2 alone
 - PFS was significantly improved with tafasitamab with R2
- 4. AZD0486 is a bispecific antibody targeting...**

 - CD3/CD20
 - CD3/CD19
 - CD3/GPRC5D
 - CD4/CD8
- 5. Which of the following best describes results with lisocabtagene maraleucel in the marginal zone lymphoma cohort of the Phase II TRANSCEND FL trial?**

 - No improvement in overall response rate (ORR)
 - Nonsignificant trend toward improved ORR
 - Statistically significant improvement in ORR